Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...